StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a report issued on Saturday morning. The firm issued a hold rating on the stock.

Separately, JMP Securities reiterated a "market outperform" rating and set a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Price Performance

NASDAQ DBVT traded down $0.53 during trading hours on Friday, reaching $4.46. The company's stock had a trading volume of 86,543 shares, compared to its average volume of 84,811. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $8.32. The stock has a market cap of $91.74 million, a P/E ratio of -0.99 and a beta of 0.71. The firm has a fifty day simple moving average of $4.46 and a 200-day simple moving average of $3.84.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the SEC. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.